Risk factors
Immunovant (IMVT) risk factors
Item 1A of every Immunovant, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors70 risks5 new2 dropped15 reworded
IMVT-1402 is now the central development and commercialization focus; batoclimab development has been discontinued.
Filed May 20, 2026 - FY2025 10-K risk factors67 risks
Clinical stage biopharmaceutical company dependent on developing and commercializing two main product candidates, batoclimab and IMVT-1402, for autoimmune diseases. Heavily reliant on the HanAll licensing agreement for core intellectual property and clinical development success. Facing intense competition and substantial capital requirements with a history of operating losses.
Filed May 29, 2025